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Modification by WR 2721 of the response to chemotherapy
of tumours and normal tissues in the mouse
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Summary The sulphydryl compound WR 2721 has been combined with a range of cytotoxic drugs in the
mouse and the effects upon tumours and normal tissues determined. In the acute lethality (LD50130) assay,
mean protection,factors produced by WR 2721 (200 or 400mgkg-') were generally less than 1.3 for
cyclophosphamide (CTX), CCNU and chlorambucil (CHL) but a protection factor of 1.7 was obtained for cis-
platinum (cis-P) in combination with 400mgkg-1 of WR 2721. No protection against the depression of
peripheral white cell count seen at 3 days after CTX, CCNU or cis-P was obtained with either 200 or
400mgkg-' of WR 2721. Significant protection of the RIF-1 sarcoma by WR 2721 against CTX and cis-P
induced growth delay was seen. In the KHT sarcoma, WR 2721 produced small reductions in the growth
delay caused by CCNU, melphalan and CHL but these were not statistically significant. These data show less
differential normal tissue protection by WR 2721 than do a number of reports in the literature.
The sulphydryl compound, WR 2721, has been
developed as a selective protector of normal tissues
against ionising radiation (Yuhas, 1980a). More
recently a number of papers have appeared which
indicate that this compound is also able to
selectively protect normal tissues in the mouse or
rat against a number of cytotoxic drugs whilst
having little or no effect upon the anti-tumour
efficacy of these agents (Yuhas, 1979; Yuhas &
Culo, 1980; Yuhas et al., 1980; Wasserman et al.,
1981). In our own study of cyclophosphamide
(CTX) in combination with WR 2721, however, we
found significant protection of two mouse tumours
against CTX, whilst seeing less protection of normal
tissues than reported by others (Twentyman, 1981).
In this paper, we report the results of a much larger
series of experiments in which protection by WR
2721 against the effects of a range of cytotoxic
drugs has been studied in both tumour and normal
tissues of the mouse.
Materials and methods
Mice and tumours
The mice used in these studies were inbred C3H/He
supplied by OLAC. Females were used in most
experiments, but males were used occasionally. Mice
entered experiments at age 12-16 weeks and
weighed 20-28g.
Tumours used were the KHT and RIF-1
sarcomas, both of which originated in C3H/Km
mice at Stanford University, California, and which
have been previously described (Kallman et al.,
1967; Twentyman, et al., 1980). The methods used
for tumour cell inoculation into the gastrocnemius
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muscle of the hind limb and subsequent
measurement of tumour growth, including
conversion of leg measurement to tumour weight,
have also been described (Twentyman et al., 1979).
The endpoint of growth delay was calculated from
the geometric means of the times taken for
individual tumours to reach 4 x the initial group-
mean treatment volume. Tumours were treated in
the size range 300-600mm3.
Nine to 12 mice were used in each treatment
group.
White-cell counts
Blood samples were taken from unanaesthetized
mice by cutting a few mm from the end of the tail
with a scalpel. A capillary pipette was then used to
draw up 0.015ml of blood, which was diluted in
20ml of "Isoton" (Coulter Electronics Ltd). Six
drops of "Zapoglobin" were added to lyse the red
cells, and counts were made on an electronic
particle counter (Coulter Electronics-Model ZBI).
Drugs
WR 2721 (S,2-(3-aminopropylamlno)ethyl-phos-
phorothioc acid) was kindly supplied by the
Drug Development Branch of the U.S. National
Cancer Institute. Most of the experiments were
carried out with a sample of batch NF LOT AJ
68.2 supplied in December 1979. We have recently
(March 1982), however, obtained a sample of batch
NH LOT AJ 68.4 and this was used in a number of
experiments specified in the Results section. Both
specimens arrived packed with dry ice and were
subsequently kept at -20°C. The drug was
dissolved in Hanks balanced salt solution
immediately before use and was injected by the i.p.
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route at a volume of O.Olmlg-1 30min before
cytotoxic drug administration. Cytotoxic drugs were
obtained, dissolved and administered as shown in
Table I.
Results
Toxicity of WR 2721 alone
In an earlier study we reported the acute LD50 (7
days) of batch AJ 68.2 in female C3H mice to be
550mgkg- . Two recent small experiments with
this same batch have produced values of 650 and
550mgkg- . In the second of these experiments
batch AJ 68.4 was also tested and gave an identical
value of 550mgkg-'.
We also found (Honess & Twentyman,
unpublished) that whereas 200mgkg-1 of batch AJ
68.2 produced essentially no change in mouse body
temperature, a dose of 400mgkg-' produced a fall
of 4-50C at 1 h after administration with recovery
by 4-6h. A comparative study of batches AJ 68.2
and AJ 68.4 has now been made and the change in
1 h body temperature with dose of WR 2721 was
similar for the 2 batches.
In view of the potential complications due to
hypothermia produced by 400mgkg-1 of WR 2721
and our previous finding of marked tumour
protection against CTX by this dose (Twentyman,
1981), many of the current experiments have used a
WR 2721 dose of 200mgkg- . A number of
experiments have, however, also included the higher
dose of400mgkg- .
Acute lethality ofcytotoxic drugs
Results of experiments to determine the median
Table I Cytotoxic drugs studied
Administered volume*
Drug Supplier Preparation (ml g-1)
Cyclophosphamide Ward Dissolve in 0.005-0.02
(CTX) Blenkinsop Ltd. HBSS
Melphalan Chester Beatty Dissolve in 0.01
(MEL) Research acidified
Institute ethanol.
Dilute 1:10
in propylene
glycol/
K2HPO4
buffer,
final pH
7.4
1-(2-chloroethyl) U.S. National Dissolve in 0.005-0.05
-3-cyclohexyl- Cancer absolute
l-nitrosourea Institute ethanol.
(CCNU) Dilute 1:20
in 0.5%
carboxy-
methyl
cellulose/
HBSS
Chlorambucil Chester Beatty Dissolve in 0.01
(CHL) Research absolute
Institute ethanol.
Dilute 1:10
in arachis
oil B.P.
Cis-dichlorodi- Mead Johnson Dissolve in 0.005-0.04
ammineplatinum Laboratories HBSS
II (cis-P)
*All drugs administered by the i.p. route.WR 2721 AND CHEMOTHERAPY 59
lethal dose (LD50) at 30 days for various cytotoxic
drugs in the presence or absence of WR 2721 are
shown in Table II. These data are based on results
of experiments in which 6 groups of 5 mice were
treated with graded doses of the cytotoxic drugs.
For CHL, most deaths occurred within 48h of drug
administration. For CCNU and cis-P almost all
deaths occurred 5-8 days after treatment. For CTX
deaths began at Day 7 and continued throughout
the 30-day observation period.
White cell count
The depression of peripheral white cell count at 3
days after CTX is shown in Figure 1. It may be
seen that no significant change in the pattern was
brought about by pretreatment with WR 2721 at
either of the dose levels used. This conclusion was
confirmed in a repeat experiment.
Similar experiments in which CCNU and cis-P
were combined with either 200 or 400mgkg-1 of
WR 2721 produced similar results to that for CTX
(i.e. no difference in depression of white cell count at
Day 3). For CCNU, white cell counts were followed
for a further 7 days and recovery was not modified
by WR 2721 treatment.
Tumour response
The effect of WR 2721 pretreatment on the anti-
Table II Effect of WR2721 on acute toxicity of cytotoxic drugs
WR
2721 LD50 LD50
Dose -WR 2721 +WR 2721
Drug (mgkg-) (mgkg-1) (mgkg- ) P.F. Note
CTX 400 217(190-244) 313 (251-375) 1.44 (1.16-1.79) a
400 273 (215-331) 334 (303-365) 1.22 (0.98-1.51) a,b
400 225 (200-250) 232 (193-272) 1.03 (0.85-1.22) a
200 252 (218-285) 374 (343-405) 1.48 (1.28-1.72) a
200 308(266-357) >450 > 1.46 c,e
200 253 (233-274) 224 (185-272) 0.89 (0.70-1.13) c
200 279 (254-305) 327 (283-378) 1.17 (0.99-1.39) d
CCNU
400 54.9 (49.1-62.9) 46.7 (40.1-54.4) 0.85 (0.71-1.01)
200 49.4 (44.2-55.3) 58.2 (44.0-52.8) 1.18 (1.02-1.37)
200 54.9 (49.1-61.4) 54.7 (50.1-59.7) 1.00 (0.86-1.15)
CHL 300 25.3 (23.8-26.9) 30.2 (27.6-33.1) 1.19 (1.07-1.32)
Cis-P 400 16.8 (13.5-20.9) 25.3 (23.1-27.7) 1.51 (1.28-1.78)
400 12.0 ( 6.5-22.2) 22.7 (20.1-25.7) 1.89 (1.01-3.53) f
400 12.0 ( 6.5-22.2) 20.6 (18.4-23.1) 1.72 (0.92-3.20) f,g
400 10.7 ( 9.0-12.8) 18.8 (17.1-20.6) 1.76 (1.44-2.14) g
200 16.8 (13.5-20.9) 19.4 (16.9-22.4) 1.15 (0.89-1.50)
200 19.1 (13.8-26.4) 20.3 (16.6-24.8) 1.06 (0.77-1.47)
Values are LD50 (95% confidence
program for probit analysis.
limits) at 30 days, computed using the GLIM
LD.50(+WR 2721) P.F. (=protection factor)=LD50( -WR 2721)
Notes
a) As previously reported (Twentyman, 1981)
b) LD50 at 100 days
c) See note d
d) Combined data for 2 preceding experiments (marked c)
e) Survival did not fall to 50% at highest CTX dose in presence of WR 2721
f) Determinations carried out within same experiment using different batches of WR
2721
g) WR 2721 batch AJ 68.460 P.R. TWFNTYMAN
Table III Effect of WR 2721 on tumour growth delay
in RIF-1
01 - U bU lUU 1bU 2UU
Dose (mg/kg)
Figure 1 Effect of WR 2721 on change in peripheral
white cell count in mice measured 3 days after various
doses of CTX. 0 CTX alone; A WR 2721
(200mgkg-1)-30min-CTX; WR 2721
(400mgkg')--30omin-CTX; S mice/group. Error
bars indicate +2 s.e. of the mean.
tumour effectiveness of the various cytotoxic drugs
is shown in Tables III and IV. It may be seen that in
the RIF-1 tumour we confirm our previous finding
of marked protection against CTX by 400mgkg-1
of WR 2721 (Twentyman, 1981). In addition we
have now also looked at the effect of growing the
tumour intradermally in the flank instead of
intramuscularly in the leg. There was again a
tendency for WR 2721 to reduce the CTX-induced
growth delay but the differences in this experiment
were not significant at the 95% confidence level.
Also in the RIF-1 tumour, protection of the tumour
against cis-P is brought about by WR 2721. The
data shown in Table III and Figure 2 indicate that
the main effect is at lower doses of cis-P, and that
for a growth delay of 4 days, the protection factor
is around 1.4.
The data shown in Table IV indicate that only
very small protection factors are seen for WR 2721
in combination with CCNU, MEL or CHL in the
KHT tumour. We do not believe that this is a
tumour difference, since in our earlier study
(Twentyman. 1981) a clear protection by WR 2721
of the KHT tumour against CTX was seen. With
such small effects, the differences in Table IV between
groups receiving the same cytotoxic drug treatment
but with or without WR 2721 are not significant in
single experiments. It is of note, however, that, of
Growth delay
Dose WR 2721 (days)
Drug (mg kg-1) Dose (2 s.e. limits) Note"
CTX 100 0 9.1 (7.8-10.4)
,, 100 400 5.7 (4.4-7.1)
CTX 50 0 2.1 (1.4-2.9) a
100 0 6.4 (4.8-8.2). a
100 200 5.1 (4.1-6.2) a
100 400 4.7 (3.9-6.0) a
Cis-P 8 0 8.9 (8.1-10.1)
,, 8 200 6.8 (5.6-8.2)
Cis-P 4 0 3.5 (1.7-5.7) b
8 0 5.9 (3.7-8.6) b
12 0 14.0 (13.6-15.5) b
4 400 0.9 (0.3-1.5) b,c
8 400 4.5 (3.2-5.8) b,c
12 400 10.3 (8.9-11.7) b,c
Notes
a) Tumours grown intra-dermally in the flank
b) These data also shown in Figure 4
c) WR 2721 batch AJ 68.4
Table IV Effect of WR 2721 on tumour
growth delay in KHT
1 2721 Growth delay
Dose Dose (days)
Drug (mg kg-1) (mg kg-1) (2 s.e. limits)
CCNU
10 0 4.8 (4.1-5.6)
20 0 13.8 (12.9-14.7)
30 0 19.1 (16.2-22.1)
20 200 12.8 (12.5-13.1)
30 200 17.8 (16.5-19.1)
30 400 16.8 (14.9-18.8)
20 0 15.1 (14.1-16.1)
20 200 15.1 (12.4-18.2)
MEL 8 0 1.1 (0.6-1.5)
12 0 5.2 (3.1-8.0)
12 200 4.5 (3.4-6.2)
12 0 8.2 (7.3-9.1)
12 200 8.0 (7.0-9.2)
CHL 7.5 0 1.6 (0.7-2.8)
15 0 8.7 (7.3-10.3)
15 200 6.6 (5.5-7.7)
15 0 9.6 (7.8-11.7)
15 200 8.0 (6.9-9.2)
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Figure 2 Growth delay in the RIF-1 tumour with
increasing dose of cis-P. * cis-P alone; 0 WR 2721
(400mgkg-) at 30min before cis-P.
the 7 experiments in which a direct comparison was
possible, the groups receiving WR 2721 showed a
smaller growth delay in 6 cases and the delays were
identical in the seventh.
Discussion
The original data on the action of WR 2721 as a
differential radioprotector of normal tissues
(summarised by Yuhas, 1980a) showed two notable
features. Firstly, the protection of a variety of
different normal tissues in the mouse and in the rat
could be obtained, with protection factors
frequently in excess of 2.0 (neural tissue, however,
being a notable exception). Secondly, with only a
rare exception, no protection of tumours was found.
More recently, however, a number of papers have
appeared which report significant radioprotection of
a number of different murine solid tumours (Rojas
et al., 1982; Clement & Johnson, 1982) and of
micrometastases in the lungs of mice (Milas et al.,
1982).
This same course of events has been followed
with regard to data on the ability of WR 2721 to
protect normal tissues selectively from the effects of
cytotoxic drugs. Reports of protection of normal
tissues against nitrogen mustard (Yuhas, 1979), cis-
P (Yuhas & Culo, 1980) and CTX (Yuhas et al.,
1980) were all accompanied by findings of a lack of
protection of tumours. Using the bone marrow
CFUs assay in LAF1 mice, Wasserman et al., (1981)
examined the ability of WR 2721 to protect against
nitrogen mustard, CTX, BCNU, cis-P and 5-
fluorouracil and obtained protection factors in the
range 1.5 to 4.6. In a parallel study of the growth
delay in EMT6 tumours little or no protection was
seen (although it is not possible to estimate
protection factors from the data). More recently,
however, our own studies with CTX (Twentyman,
1981) and those of Clement & Johnson (1982) with
MEL and CTX have shown significant protection.
It must therefore be recognised that differential
radio- and chemo-protection by WR 2721 are by no
means absolute and that detailed studies of
therapeutic ratios using a variety of normal tissue
endpoints are required.
The dose of WR 2721 used and its time of
administration with respect to radiation or
cytotoxic drugs are important parameters to be
considered in any study of interactions. In most
radiation studies a time of 15-30min has been
chosen as this allows peak levels of drug to be
attained in most normal tissues whilst allowing little
time for the slower absorption into tumours (Yuhas,
1980b). A similar rationale has been used in
chemoprotection experiments (Yuhas, 1979; Yuhas
& Culo, 1980; Yuhas et al., 1980; Twentyman,
1981). A potential artefact of drug interaction in the
bloodstream has, however, been pointed out when
very short times (5-15min for nitrogen mustard) are
used (Yuhas, 1979).
Doses of WR 2721 used have generally been in
the range of 200-600mgkg-1. In studies of
radiation-induced haemopoietic death in 4 strains of
mice, Yuhas (1980a) found that a protection factor
of 2.0 was achieved at a WR 2721 dose of
200mgkg-1, compared with a value of 2.7 in the
dose range 400-600mgkg- . For radiation damage
to the mouse jejunum, a plateau of protection was
achieved at a WR 2721 dose of 200mgkg-t,
although further protection was seen in the mouse
testis by increasing the dose from 300-500mgkg-1
(Milas et al., 1982). Chemoprotection against
nitrogen mustard (30-day survival) gave a
protection factor of 1.5 for 200mgkg1 of WR 2721
compared with 1.9-2.0 at 400mgkg 1, subsequently
falling back to 1.5 at 500mgkg-' (Yuhas, 1979).
Protection against the renal toxicity of cis-P in the
mouse (as measured by day-5 elevation of blood
urea nitrogen) was by factors of 1.2 and 1.5 at
WR 2721 doses of 100 and 200mgkg-' respectively
(Yuhas et al., 1980). In summary, therefore,
although increases in protection factors are
sometimes seen above a dose of 200mgkg- 1 of WR
2721, the major component of protection is usually
seen at this dose level with typical protection
factors of around 1.5.
The data presented in this paper are, therefore,
somewhat at variance with other reports on
differential chemoprotection. In our earlier paper
(Twentyman, 1981) we obtained a mean protection
factor of 1.25 for 400mgkg-t of WR 2721 with62 P.R. TWENTYMAN
CTX. A single experiment using 200mgkg-I,
however, gave a higher protection factor of 1.48.
Two further experiments, now reported in this
paper give a combined value of 1.17 for
200mgkg-1, thus reducing the weight of the earlier
relatively high value. For CCNU, the mean value at
200mgkg- is 1.1, whereas a single experiment at
400mgkg- gave no protection (factor=0.85).
Similarly for 300mgkg-1 of WR 2721 in
conjunction with CHL a protection factor of 1.19
was obtained. For WR 2721 together with cis-P, a
marked dose dependence was seen, values of 1.06
and 1.15 being obtained at 200mgkg- of WR
2721 but four values between 1.5 and 1.9 at
400mgkg-'.
Using depression of peripheral white cell count at
Day 3 after drug treatment, however, we found no
protection against CTX, CCNU, or cis-P at either
200 or 400mgkg-' of WR 2721. This result, in
particular, is in marked contrast with data of
Wasserman et al., (1981) where protection factors
for mouse bone marrow CFUs of 2.4 and 3.2 were
obtained for CTX and cis-P respectively (together
with values of 4.6 and 1.5 for nitrogen mustard and
BCNU). Clearly there are considerable differences in
the target cell populations for the two assays. The
3-day nadir of white cell count is likely to reflect
the effect of the drugs mainly upon the proliferating
committed precursors of the white cell series with
the subsequent recovery rate being determined by
the earlier precursors (including CFUs). Although
most progenitors of the granulocyte series are
located in the bone marrow, lymphoid precursors
are more widely distributed. As around 70% of
peripheral white cells in the mouse are lymphocytes,
drug effects in sites other than the marrow will be
very important in determining the Day 3 peripheral
count. Site-dependent differences in drug levels or in
the degree of interaction between WR 2721 and the
various cytotoxic drugs may, therefore, be involved
in these conflicting results. In addition, it should be
noted that the CFUs assays in the study of
Wasserman et al., were carried out at 2h after drug
administration. It is likely that a 5°C drop in mouse
body temperature (as caused by 400mgkg-t of WR
2721-see Materials and methods) will cause
considerable changes in cytotoxic drug activation
and metabolism and the use of such a short time of
assay may be misleading if drug availability times
are considerably prolonged. This problem does not,
of course, arise when considering an in situ
endpoint such as white cell count depression.
We have confirmed our earlier finding of tumour
protection against CTX by WR 2721, being greater
at 400mgkg-1 than at 200mgkg-l. We have also
found protection against cis-P at 200 and
400mgkg-' of WR 2721. For the other cytotoxic
agents there appeared to be a trend towards
tumour protection, but with very small protection
factors.
In conclusion, therefore, our data for differential
chemoprotection by WR 2721 are distinctly less
encouraging than the balance of other data in the
literature. In most of our LD50 experiments, the
protection factors were very small and in none of
our white cell count experiments was significant
protection seen. Only for cis-P in combination with
400mgkg-1 of WR 2721 was protection in excess
of 1.5 seen for LD50. For this drug (and for CCNU)
almost all deaths in the LD50/30 experiments occur
5-8 days after drug administration and are likely to
be due to gastrointestinal damage. This LD50 factor
may therefore be indicative of considerable
variations in protection factors between various
critical tissues. As the tumour protection factor for
this combination is < 1.2 at cis-P doses in the LD50
region, then differential chemoprotection may occur
and thus this combination may be worthy of further
study.
I thank Daryl Knight and Kate Smith for their technical
assistance.
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